Axa
KDNY

Axa’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Axa’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,200
Closed -$216K – 1246
2022
Q1 		$216K Sell
13,200
-5,900
-31% -$80.2K ﹤0.01% 1144
2021
Q4 		$312K Sell
19,100
-4,400
-19% -$62.6K ﹤0.01% 1081
2021
Q3 		$300K Buy
+23,500
New +$309K ﹤0.01% 1143
2020
Q3 		– Sell
-16,980
Closed -$196K – 1372
2020
Q2 		$196K Sell
16,980
-21,711
-56% -$299K ﹤0.01% 1182
2020
Q1 		$530K Sell
38,691
-10,300
-21% -$122K ﹤0.01% 959
2019
Q4 		$289K Hold
48,991
– – ﹤0.01% 1080
2019
Q3 		$260K Sell
48,991
-1,980
-4% -$13.1K ﹤0.01% 1211
2019
Q2 		$392K Sell
50,971
-7,977
-14% -$121K ﹤0.01% 1114
2019
Q1 		$1.17M Buy
58,948
+31,817
+117% +$555K ﹤0.01% 944
2018
Q4 		$358K Buy
27,131
+18,580
+217% +$371K ﹤0.01% 1145
2018
Q3 		$314K Buy
8,551
+3,951
+86% +$127K ﹤0.01% 1221
2018
Q2 		$161K Buy
+4,600
New +$176K ﹤0.01% 1317

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's KDNY Position: Q2 2022 in Review

Axa sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2022, closing a stake of 13,200 shares — an estimated $216K sold.

Axa first reported a position in KDNY in Q2 2018 and held it in 12 quarters. The position peaked at $1.17M in Q1 2019. 135 funds tracked by Wall St. Rank hold KDNY as of Q2 2022.

  • Axa reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Axa sold 13,200 Chinook Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $216K.
  • Axa first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2018 and held it in 12 quarters.
  • Axa's Chinook Therapeutics, Inc. Common Stock position peaked at $1.17M in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.